Maël Donoso of Ouroboros Neurotechnologies (Lausanne) published 'Human Brain Zero' in Frontiers in Neuroscience this week — sole-author, under his company's affiliation rather than an academic post, paired with two working public GitHub artifacts (an EEG-to-fMRI predictor and a neurofeedback API). The paper coins "consciousness engineering" as a research domain. lucidcode released INSPEC the same week, the first contactless lucid dreaming device — a night-vision smart camera that detects REM eye movements and triggers audio cues from across the room rather than from a headband. A 299-participant medRxiv RCT reported sustained reductions in internalizing symptoms from a 10-minute-per-day fully remote focused-attention meditation.

In policy, six days after Trump signed the April 18 executive order, the FDA awarded the first-ever fast-track designations to three psychedelic platforms in a single day — Compass Pathways' COMP360, Usona's PSIL201, and Transcend's methylone — designed to compress NDA review from 10-12 months to one to two. ARPA-H awarded $139.4M to 13 behavioral-health teams three days earlier, with awardees including INVI MindHealth's real-time biomarker platform and a University of Wisconsin team studying transcutaneous vagus nerve stimulation augmentation of psilocybin sessions. Compass moved the same week to lock in the small-clinic delivery layer via a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices.

The week's pattern: research-to-product activity advanced on three independent Spirit Tech tracks — a private neurotech company publishing under company affiliation, an n=299 meditation RCT, and a hardware launch in a previously-headband-bound category — while the federal apparatus moved as a coordinated stack on psychedelics. The ibogaine prep/integration tech gap flagged in last week's digest started closing within four to six days of the executive order: Optimi Health extended its GMP supply platform to ibogaine, and Ibogaine by David Dardashti announced an algorithmic-dosing protocol with continuous physiological monitoring.